INKT
What one share of MiNK Therapeutics holds
Biological Products, (No Diagnostic Substances)
MiNK Therapeutics, Inc. (“we,” “our,” or “MiNK”) is focused on developing innovative treatments for cancer and immune-mediated diseases using allogeneic, ex-vivo expanded invariant natural killer T ("iNKT") cells. Amid a broader industry renaissance in innate immunity—highlighted by surging investment and clinical activity in NK, γδ T, and iNKT-based therapies—iNKT cells represent a distinct T cell (“T”) population that uniquely bridges innate and adaptive immunity.
MiNK Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.40 |
|---|---|
| Cash and investments | $1.73 |
| Book value | −$2.75 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$6.74 | $0.04 | −$3.50 | — | −$22.35 |
| 2021 | — | −$11.61 | $0.10 | −$5.02 | — | $7.10 |
| 2022 | — | −$8.31 | $0.07 | −$5.68 | — | −$0.12 |
| 2023 | — | −$6.54 | $0.02 | −$4.61 | — | −$5.22 |
| 2024 | — | −$2.86 | — | −$2.53 | — | −$4.94 |
| 2025 | — | −$2.93 | — | −$1.39 | — | −$3.02 |